316 related articles for article (PubMed ID: 30926829)
1. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.
Tormo E; Ballester S; Adam-Artigues A; Burgués O; Alonso E; Bermejo B; Menéndez S; Zazo S; Madoz-Gúrpide J; Rovira A; Albanell J; Rojo F; Lluch A; Eroles P
Sci Rep; 2019 Mar; 9(1):5316. PubMed ID: 30926829
[TBL] [Abstract][Full Text] [Related]
2. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
[TBL] [Abstract][Full Text] [Related]
3. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.
Tormo E; Pineda B; Serna E; Guijarro A; Ribas G; Fores J; Chirivella E; Climent J; Lluch A; Eroles P
J Cell Biochem; 2015 Sep; 116(9):2061-73. PubMed ID: 25802200
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
6. New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells.
Ciocan-Cartita CA; Jurj A; Zanoaga O; Cojocneanu R; Pop LA; Moldovan A; Moldovan C; Zimta AA; Raduly L; Pop-Bica C; Buse M; Budisan L; Virag P; Irimie A; Gomes Dias SM; Berindan-Neagoe I; Braicu C
J Exp Clin Cancer Res; 2020 Nov; 39(1):241. PubMed ID: 33187552
[TBL] [Abstract][Full Text] [Related]
7. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1.
Li Y; Liang Y; Sang Y; Song X; Zhang H; Liu Y; Jiang L; Yang Q
Cell Death Dis; 2018 Jan; 9(1):14. PubMed ID: 29323124
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
[TBL] [Abstract][Full Text] [Related]
9. Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein.
Abd-Ellatef GEF; Gazzano E; El-Desoky AH; Hamed AR; Kopecka J; Belisario DC; Costamagna C; S Marie MA; Fahmy SR; Abdel-Hamid AZ; Riganti C
Pharmacol Res; 2022 Jan; 175():105975. PubMed ID: 34785319
[TBL] [Abstract][Full Text] [Related]
10. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization, and in vitro tumor-suppressive effect of anti-miR-21-equipped RNA nanoparticles.
Zhang T; Wu Y; Yang D; Wu C; Li H
Biochem Biophys Res Commun; 2021 Jun; 558():107-113. PubMed ID: 33906109
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
13. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.
Tudoran O; Soritau O; Balacescu L; Visan S; Barbos O; Cojocneanu-Petric R; Balacescu O; Berindan-Neagoe I
Mol Cell Biochem; 2015 Nov; 409(1-2):163-76. PubMed ID: 26187676
[TBL] [Abstract][Full Text] [Related]
14. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
[TBL] [Abstract][Full Text] [Related]
15. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
16. [Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer].
Ma T; Zhang J; Wu J; Tang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 May; 39(5):488-95. PubMed ID: 24921394
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
[TBL] [Abstract][Full Text] [Related]
18. Aryl hydrocarbon receptor counteracts pharmacological efficacy of doxorubicin via enhanced AKR1C3 expression in triple negative breast cancer cells.
Yamashita N; Kanno Y; Saito N; Terai K; Sanada N; Kizu R; Hiruta N; Park Y; Bujo H; Nemoto K
Biochem Biophys Res Commun; 2019 Aug; 516(3):693-698. PubMed ID: 31253396
[TBL] [Abstract][Full Text] [Related]
19. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs.
Chen WX; Liu XM; Lv MM; Chen L; Zhao JH; Zhong SL; Ji MH; Hu Q; Luo Z; Wu JZ; Tang JH
PLoS One; 2014; 9(4):e95240. PubMed ID: 24740415
[TBL] [Abstract][Full Text] [Related]
20. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
